Dermira (NASDAQ: DERM) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.
Volatility and Risk
Dermira has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Dermira and Microbot Medical, as reported by MarketBeat.
||Strong Buy Ratings
Dermira currently has a consensus target price of $32.71, indicating a potential upside of 246.92%. Microbot Medical has a consensus target price of $1.75, indicating a potential upside of 108.33%. Given Dermira’s higher probable upside, analysts clearly believe Dermira is more favorable than Microbot Medical.
Earnings and Valuation
This table compares Dermira and Microbot Medical’s gross revenue, earnings per share and valuation.
||Earnings Per Share
Microbot Medical has lower revenue, but higher earnings than Dermira. Dermira is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
This table compares Dermira and Microbot Medical’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Institutional & Insider Ownership
94.7% of Dermira shares are owned by institutional investors. Comparatively, 5.1% of Microbot Medical shares are owned by institutional investors. 13.3% of Dermira shares are owned by insiders. Comparatively, 31.8% of Microbot Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Microbot Medical beats Dermira on 8 of the 14 factors compared between the two stocks.
Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.
About Microbot Medical
Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.